본문 바로가기
KERD
논문KCI 등재

2형 당뇨병을 위한 새로운 약제: 글루카곤양 펩티드-1 (GLP-1) 유사체

New Treatment for Type 2 Oiabetes: GLP-1 Analogue

오승준
대한가정의학회 (The Korean Academy Of Family Medicine)|2006.11|Korean Journal of Family Medicine|제27권 제11호|pp. 863-872

1

조회

0

다운로드

1

인용

0

참고문헌

주제분류가정의학

초록

글루카곤양 펩티드-1 (GLP-1)은 인크레틴 호르몬으로 장관 내 영양분에 자극을 받아 분비되며, 포도당 농도에 따른 인슐린 분비를 증강시키는 특징이 있어, 강력한 인슐린 분비 자극 효과가 있는 데 반해, 저혈당이 생기지 않는 장점이 있어 당뇨병 치료의 새로운 후보 약물이다. 그러나 생체 내 반감기가 약 2분 정도로 짧아, 치료 약제로 개발하는 데 해결하기 힘든 문제가 있어왔다. 최근 생물학적 반감기가 긴 GLP-1 유사체가 개발되고, GLP-1을 파괴시키는 Dipeptidyl peptidase-IV (DPP-IV) 억제제가 개발되어 새로운 2형 당뇨병 치료제로서의 본격적인 사용을 앞두고 있다. 현재까지 이들 약제의 임상시험 결과로는 기존의 당뇨병 약제의 단점으로 여겨졌던 체중 증가가 없거나 감소되는 특징이 있으며, 식후 고혈당의 개선에 효과적이며, 일정 기간 사용할 경우 인슐린 분비능이 개선되는 장점들이 보고되고 있다. 또한 기존의 당뇨병 약제들이 제공하지 못하거나 단점으로 지적되던 부분에 대해 이 새로운 계열의 약제가 제공해 줄 수 있는 기대효과가 있어, 기존의 당뇨병 치료제와의 새로운 병합 요법이 가능해져 당뇨병 치료에 도움이 될 것으로 기대된다.

참고문헌 (43)

  1. Holst JJ, "Glucagonlike peptide 1: a newly discovered gastrointestinal hormone.", Gastroenterology, 107(6), pp.1848~1855 (1994)
  2. Fehmann HC, "Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.", Endocr Rev, 16(3), pp.390~410 (1995)
  3. Xu G,, "Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.", Diabetes, 48(12), pp.2270~2276 (1999)
  4. Stoffers DA, "Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.", Diabetes, 49(5), pp.741~748 (2000)
  5. Perfetti R, "Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.", Endocrinology, 141(12), pp.1600~1605 (2000)
  6. on endocrine secretion from pig pancreas, antrum, and nonantral stomach, "Endocrinology", 1988, 2009~2013
  7. Wettergren A, "runcated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.", Dig Dis Sci, 38(4), pp.665~673 (1993)
  8. Nauck MA, "Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.", Am J Physiol, 273(5 Pt), pp.E981~E988 (1997)
  9. Holst JJ, "Enteroglucagon.", Annu Rev Physiol, (59), pp.257~271 (1997)
  10. Flint A, "Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.", J Clin Invest, 101(3), pp.515~520 (1998)
  11. Naslund E, "Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men", Int J Obes Relat Metab Disord, 23(3), pp.304~311 (1999)
  12. Gutzwiller JP, "Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.", Am J Physiol, 276(5 Pt 2), pp.1541~1544 (1999)
  13. Nauck MA, "Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.", Diabetologia, 36(8), pp.741~744 (1993)
  14. Nauck MA, "Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.", Diabetes Care, 21(11), pp.1925~1931 (1998)
  15. Nauck MA, "Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.", Horm Metab Res, 29(9), pp.411~416 (1997)
  16. Toft-Nielsen MB, "Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.", J Clin Endocrinol Metab, 86(8), pp.3717~3723 (2001)
  17. Rachman J, "Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.", Diabetologia, 40(2), pp.205~211 (1997)
  18. Larsen J, "Glucagon-like peptide-1 infusion must be maintained for 24 h", day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment., 2001, pp.24(8), 1416~1421
  19. Deacon CF, "Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity", Diabetologia, 41(3), pp.271~278 (1998)
  20. Thorens B, "loning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.", Diabetes, 42(11), pp.1678~1682 (1993)
  21. Egan JM, "The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.", J Clin Endocrinol Metab, 87(3), pp.1282~1290 (2002)
  22. Fineman MS, "Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and", or sulfonylurea treatment in patients with type 2 diabetes, 2003, pp.26(8), 2370~2377
  23. Buse JB, "Baron AD; Exenatide 113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea- treated patients with type 2 diabetes.", Diabetes Care, 27(11), pp.2628~2635 (2004)
  24. Fineman MS, "Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.", Diabetes Metab Res Rev, 20(5), pp.411~417 (2004)
  25. Agerso H, "The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.", Diabetologia, 45(2), pp.195~202 (2002)
  26. Elbrond B, "Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.", Diabetes Care, 25(8), pp.1398~1404 (2002)
  27. Juhl CB, "Bedtime administration of NN2211, a long- acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes", Diabetes, 51(2), pp.424~429 (2002)
  28. Ribel U, "NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs", Eur J Pharmacol, 451(2), pp.217~225 (2002)
  29. Rolin B, "The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.", Am J Physiol Endocrinol Metab, 283(4), pp.E745~E752 (2002)
  30. Madsbad S, "NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12- week, double-blind, randomized, controlled trial", Diabetes Care, 27(6), pp.1335~1342 (2004)
  31. Kim JG, "Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.", Diabetes, 52(3), pp.751~759 (2003)
  32. Holst JJ, "Inhibition of the activity of dipeptidyl- peptidase IV as a treatment for type 2 diabetes.", Diabetes, 47(11), pp.1663~1670 (1998)
  33. Deacon CF, "Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig", Diabetes, 47(5), pp.764~769 (1998)
  34. Ahren B, "Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.", Eur J Pharmacol, 404(1-2), pp.239~245 (2000)
  35. Ahren B, "Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.", Diabetes Care, 25(5), pp.869~875 (2002)
  36. Ahren B, "Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes", J Clin Endocrinol Metab, 89(5), pp.2078~2084 (2004)
  37. Ahren B, "Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.", Diabetes Care, 27(12), pp.2874~2880 (2004)
  38. Ahren B, "Improved meal- related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.", Diabetes Care, 28(8), pp.1936~1940 (2005)
  39. Ristic S, "Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response", Diabetes Obes Metab, 7(6), pp.692~698 (2005)
  40. Herman GA, "Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo- controlled studies with single oral doses", Clin Pharmacol Ther, 78(6), pp.675~688 (2005)
  41. Bergman AJ, "De Smet M, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.", Clin Ther, 28(1), pp.55~72 (2006)
  42. Augeri DJ, "Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.", J Med Chem, 48(15), pp.5025~5037 (2005)
  43. Uwaifo GI, "Novel pharmacologic agents for type 2 diabetes.", Endocrinol Metab Clin North Am, 34(1), pp.155~197 (2005)

관련 논문AI추천

제2형 당뇨병 환자에게 인크레틴 기반 약물치료요법김헌성, 김현아한국임상약학회 · 한국임상약학회지2011 · 제21권 제2호Dipeptidyl Peptidase-4 (DPP-4) 억제제이대호대한내과학회 · 대한내과학회지2014 · 제87권 제1호2형 당뇨병의 새로운 치료고정민대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2009 · 제14권 제1호Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes이동윤, 이승아대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2017 · 제22권 제1호글루카곤양펩티드-1의 췌장 외 효과정인경대한내과학회 · 대한내과학회지2015 · 제89권 제4호제 2형 당뇨병 치료제의 개발 동향김익환, 이수현, 이종근한국미생물·생명공학회 · 한국미생물·생명공학회지2012 · 제40권 제3호

이 간행물의 다른 논문 (7건)

RAND 방법을 이용한 무릎 골관절염 권고 사항에 대한 일관성, 적용성, 일반화 가능성 평가엄완식, 이희영, 김철환, 이찬희, 김진구, 김남순, 김수영, 지종대, 배상철pp. 873-882가정의학 전공 학위논문 분석성낙진, 이동욱, 박기흠, 하기훈, 장철원, 정재욱pp. 883-888일개 대학병원 가정의학과의 가정형 호스피스 케어 서비스 경험이정권, 김준수, 이하영, 강석훈, 정화경pp. 889-894일개 대학 병원에 종합검진을 위하여 내원한 환자들의 신장질환 유병률과 관련된 요인유창주, 조희경, 조동영, 최재경, 이석호, 권혁중, 도현진, 박민수pp. 895-903체성분분석기 InBody 4.0과 허리둘레에 의한 내장형비만 평가의 정확도강지현, 김선경, 유병연, 전희선pp. 904-910
원문 보기